JPMorgan Chase & Co. Decreases Stock Holdings in Medpace Holdings, Inc. $MEDP

JPMorgan Chase & Co. cut its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 33.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 177,853 shares of the company’s stock after selling 87,417 shares during the period. JPMorgan Chase & Co.’s holdings in Medpace were worth $91,445,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Norges Bank acquired a new stake in shares of Medpace in the 2nd quarter worth approximately $66,597,000. Clarkston Capital Partners LLC acquired a new position in Medpace during the second quarter worth $40,569,000. Mawer Investment Management Ltd. boosted its position in Medpace by 17.4% during the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after purchasing an additional 121,213 shares in the last quarter. Bares Capital Management Inc. grew its holdings in Medpace by 319.2% in the second quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock valued at $49,302,000 after purchasing an additional 119,608 shares during the last quarter. Finally, Wasatch Advisors LP grew its holdings in Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $444.96 on Tuesday. The company has a 50-day simple moving average of $553.73 and a 200-day simple moving average of $539.55. The company has a market cap of $12.63 billion, a PE ratio of 29.08, a price-to-earnings-growth ratio of 2.17 and a beta of 1.42. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.49. The business had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on MEDP shares. Truist Financial decreased their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Mizuho set a $582.00 target price on shares of Medpace in a research report on Wednesday, February 11th. Zacks Research lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Finally, TD Cowen raised Medpace from a “sell” rating to a “hold” rating and reduced their target price for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Four investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $483.45.

Insider Activity

In other news, CEO August J. Troendle sold 668 shares of Medpace stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the sale, the chief executive officer owned 646,184 shares of the company’s stock, valued at $381,694,426.96. The trade was a 0.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 80,328 shares of company stock worth $48,219,399 in the last 90 days. 20.30% of the stock is owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.